Association Between Metformin Use and Risk of Prostate Cancer and Its Grade
Metformin is commonly prescribed to treat type 2 diabetes. Recent evidence suggests that it may possess antitumoral properties. The aim of this study was to test the association between metformin use and risk of prostate cancer and its grade among men with diabetes. Data were obtained from populatio...
Gespeichert in:
| Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 2013-08, Vol.105 (15), p.1123-1131 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1131 |
|---|---|
| container_issue | 15 |
| container_start_page | 1123 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 105 |
| creator | MARGEL, David URBACH, David LIPSCOMBE, Lorraine L BELL, Chaim M KULKARNI, Girish AUSTIN, Peter C FLESHNER, Neil |
| description | Metformin is commonly prescribed to treat type 2 diabetes. Recent evidence suggests that it may possess antitumoral properties. The aim of this study was to test the association between metformin use and risk of prostate cancer and its grade among men with diabetes.
Data were obtained from population-based health-care administrative databases in Ontario, Canada. This retrospective cohort study used a nested case-control approach to examine the relationship between metformin exposure and the risk of prostate cancer within a cohort of incident diabetic men aged 66 years or older. We conducted four case-control analyses, defining case subjects as 1) any prostate cancer, 2) high-grade, 3) low-grade, and 4) biopsy-diagnosed. In each analysis, case subjects were matched to five control subjects on age and cohort entry date. Metformin exposure was determined based on prescriptions before cancer diagnosis, and adjusted odds ratios (aOR) were estimated using conditional logistic regression. All statistical tests were two-sided.
Within our cohort of 119 315 men with diabetes, there were 5306 case subjects with prostate cancer and 26 530 matched control subjects. Within the cancer case subjects, 1104 had high- grade cancer, 1719 had low-grade cancer, and 3524 had biopsy-diagnosed cancer. There was no association between metformin use and risk of any prostate cancer (aOR = 1.03, 95% confidence interval [CI] = 0.96 to 1.1), high-grade cancer (aOR = 1.13, 95% CI = 0.96 to 1.32), low-grade cancer (aOR = 0.94, 95% CI = 0.82 to 1.06), or biopsy-diagnosed cancer (aOR = 0.98, 95% CI = 0.84 to 1.02).
This large study did not find an association between metformin use and risk of prostate cancer among older men with diabetes, regardless of cancer grade or method of diagnosis. |
| doi_str_mv | 10.1093/jnci/djt170 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1437579022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1437579022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-9b2fa30235238ec353d59320e60b280663ac0446d0b8962634689bde58c73f2f3</originalsourceid><addsrcrecordid>eNqN0c9LHDEUB_BQlLpue-pdAkUolNGX35njutStuFIp9TxkMm9g1t0Zm2QQ_3uz7raCJ3N5h3x4JN8vIV8YnDEoxfmq9915s0rMwAcyYVJDwRmoAzIB4Kaw1sgjchzjCvIpufxIjriwSoDSE3I9i3HwnUvd0NMLTI-IPb3B1A5h0_X0LiJ1fUN_d_GeDi29DUNMLiGdu95jeLm7SpEugmvwEzls3Tri5_2ckrvLH3_mP4vlr8XVfLYsvLQiFWXNWyeAC5WfgV4o0ahScEANNbegtXAepNQN1LbUXAupbVk3qKw3ouWtmJJvu70PYfg7YkzVpose12vX4zDGiklhlCmB83dQbgCkZSrTr2_oahhDnz-yVcBZyazM6vtO-ZxEDNhWD6HbuPBUMai2dVTbOqpdHVmf7HeO9Qab__Zf_hmc7oGL3q3bkGPt4qsz2ljFrXgGtB6P8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1420219184</pqid></control><display><type>article</type><title>Association Between Metformin Use and Risk of Prostate Cancer and Its Grade</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>MARGEL, David ; URBACH, David ; LIPSCOMBE, Lorraine L ; BELL, Chaim M ; KULKARNI, Girish ; AUSTIN, Peter C ; FLESHNER, Neil</creator><creatorcontrib>MARGEL, David ; URBACH, David ; LIPSCOMBE, Lorraine L ; BELL, Chaim M ; KULKARNI, Girish ; AUSTIN, Peter C ; FLESHNER, Neil</creatorcontrib><description>Metformin is commonly prescribed to treat type 2 diabetes. Recent evidence suggests that it may possess antitumoral properties. The aim of this study was to test the association between metformin use and risk of prostate cancer and its grade among men with diabetes.
Data were obtained from population-based health-care administrative databases in Ontario, Canada. This retrospective cohort study used a nested case-control approach to examine the relationship between metformin exposure and the risk of prostate cancer within a cohort of incident diabetic men aged 66 years or older. We conducted four case-control analyses, defining case subjects as 1) any prostate cancer, 2) high-grade, 3) low-grade, and 4) biopsy-diagnosed. In each analysis, case subjects were matched to five control subjects on age and cohort entry date. Metformin exposure was determined based on prescriptions before cancer diagnosis, and adjusted odds ratios (aOR) were estimated using conditional logistic regression. All statistical tests were two-sided.
Within our cohort of 119 315 men with diabetes, there were 5306 case subjects with prostate cancer and 26 530 matched control subjects. Within the cancer case subjects, 1104 had high- grade cancer, 1719 had low-grade cancer, and 3524 had biopsy-diagnosed cancer. There was no association between metformin use and risk of any prostate cancer (aOR = 1.03, 95% confidence interval [CI] = 0.96 to 1.1), high-grade cancer (aOR = 1.13, 95% CI = 0.96 to 1.32), low-grade cancer (aOR = 0.94, 95% CI = 0.82 to 1.06), or biopsy-diagnosed cancer (aOR = 0.98, 95% CI = 0.84 to 1.02).
This large study did not find an association between metformin use and risk of prostate cancer among older men with diabetes, regardless of cancer grade or method of diagnosis.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djt170</identifier><identifier>PMID: 23853056</identifier><identifier>CODEN: JNCIEQ</identifier><language>eng</language><publisher>Cary, NC: Oxford University Press</publisher><subject>Age ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Canada - epidemiology ; Case-Control Studies ; Databases, Factual ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Drug Prescriptions ; Humans ; Hypoglycemic Agents - therapeutic use ; Logistic Models ; Male ; Medical research ; Medical sciences ; Mens health ; Metformin - therapeutic use ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Grading ; Nephrology. Urinary tract diseases ; Odds Ratio ; Prostate cancer ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - prevention & control ; Retrospective Studies ; Risk factors ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2013-08, Vol.105 (15), p.1123-1131</ispartof><rights>2014 INIST-CNRS</rights><rights>Copyright Oxford Publishing Limited(England) Aug 7, 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-9b2fa30235238ec353d59320e60b280663ac0446d0b8962634689bde58c73f2f3</citedby><cites>FETCH-LOGICAL-c483t-9b2fa30235238ec353d59320e60b280663ac0446d0b8962634689bde58c73f2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27678528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23853056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MARGEL, David</creatorcontrib><creatorcontrib>URBACH, David</creatorcontrib><creatorcontrib>LIPSCOMBE, Lorraine L</creatorcontrib><creatorcontrib>BELL, Chaim M</creatorcontrib><creatorcontrib>KULKARNI, Girish</creatorcontrib><creatorcontrib>AUSTIN, Peter C</creatorcontrib><creatorcontrib>FLESHNER, Neil</creatorcontrib><title>Association Between Metformin Use and Risk of Prostate Cancer and Its Grade</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Metformin is commonly prescribed to treat type 2 diabetes. Recent evidence suggests that it may possess antitumoral properties. The aim of this study was to test the association between metformin use and risk of prostate cancer and its grade among men with diabetes.
Data were obtained from population-based health-care administrative databases in Ontario, Canada. This retrospective cohort study used a nested case-control approach to examine the relationship between metformin exposure and the risk of prostate cancer within a cohort of incident diabetic men aged 66 years or older. We conducted four case-control analyses, defining case subjects as 1) any prostate cancer, 2) high-grade, 3) low-grade, and 4) biopsy-diagnosed. In each analysis, case subjects were matched to five control subjects on age and cohort entry date. Metformin exposure was determined based on prescriptions before cancer diagnosis, and adjusted odds ratios (aOR) were estimated using conditional logistic regression. All statistical tests were two-sided.
Within our cohort of 119 315 men with diabetes, there were 5306 case subjects with prostate cancer and 26 530 matched control subjects. Within the cancer case subjects, 1104 had high- grade cancer, 1719 had low-grade cancer, and 3524 had biopsy-diagnosed cancer. There was no association between metformin use and risk of any prostate cancer (aOR = 1.03, 95% confidence interval [CI] = 0.96 to 1.1), high-grade cancer (aOR = 1.13, 95% CI = 0.96 to 1.32), low-grade cancer (aOR = 0.94, 95% CI = 0.82 to 1.06), or biopsy-diagnosed cancer (aOR = 0.98, 95% CI = 0.84 to 1.02).
This large study did not find an association between metformin use and risk of prostate cancer among older men with diabetes, regardless of cancer grade or method of diagnosis.</description><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Canada - epidemiology</subject><subject>Case-Control Studies</subject><subject>Databases, Factual</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Drug Prescriptions</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mens health</subject><subject>Metformin - therapeutic use</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Grading</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Odds Ratio</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - prevention & control</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c9LHDEUB_BQlLpue-pdAkUolNGX35njutStuFIp9TxkMm9g1t0Zm2QQ_3uz7raCJ3N5h3x4JN8vIV8YnDEoxfmq9915s0rMwAcyYVJDwRmoAzIB4Kaw1sgjchzjCvIpufxIjriwSoDSE3I9i3HwnUvd0NMLTI-IPb3B1A5h0_X0LiJ1fUN_d_GeDi29DUNMLiGdu95jeLm7SpEugmvwEzls3Tri5_2ckrvLH3_mP4vlr8XVfLYsvLQiFWXNWyeAC5WfgV4o0ahScEANNbegtXAepNQN1LbUXAupbVk3qKw3ouWtmJJvu70PYfg7YkzVpose12vX4zDGiklhlCmB83dQbgCkZSrTr2_oahhDnz-yVcBZyazM6vtO-ZxEDNhWD6HbuPBUMai2dVTbOqpdHVmf7HeO9Qab__Zf_hmc7oGL3q3bkGPt4qsz2ljFrXgGtB6P8Q</recordid><startdate>20130807</startdate><enddate>20130807</enddate><creator>MARGEL, David</creator><creator>URBACH, David</creator><creator>LIPSCOMBE, Lorraine L</creator><creator>BELL, Chaim M</creator><creator>KULKARNI, Girish</creator><creator>AUSTIN, Peter C</creator><creator>FLESHNER, Neil</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U1</scope><scope>7U2</scope><scope>7X8</scope></search><sort><creationdate>20130807</creationdate><title>Association Between Metformin Use and Risk of Prostate Cancer and Its Grade</title><author>MARGEL, David ; URBACH, David ; LIPSCOMBE, Lorraine L ; BELL, Chaim M ; KULKARNI, Girish ; AUSTIN, Peter C ; FLESHNER, Neil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-9b2fa30235238ec353d59320e60b280663ac0446d0b8962634689bde58c73f2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Canada - epidemiology</topic><topic>Case-Control Studies</topic><topic>Databases, Factual</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Drug Prescriptions</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mens health</topic><topic>Metformin - therapeutic use</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Grading</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Odds Ratio</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - prevention & control</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MARGEL, David</creatorcontrib><creatorcontrib>URBACH, David</creatorcontrib><creatorcontrib>LIPSCOMBE, Lorraine L</creatorcontrib><creatorcontrib>BELL, Chaim M</creatorcontrib><creatorcontrib>KULKARNI, Girish</creatorcontrib><creatorcontrib>AUSTIN, Peter C</creatorcontrib><creatorcontrib>FLESHNER, Neil</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>MEDLINE - Academic</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MARGEL, David</au><au>URBACH, David</au><au>LIPSCOMBE, Lorraine L</au><au>BELL, Chaim M</au><au>KULKARNI, Girish</au><au>AUSTIN, Peter C</au><au>FLESHNER, Neil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association Between Metformin Use and Risk of Prostate Cancer and Its Grade</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>2013-08-07</date><risdate>2013</risdate><volume>105</volume><issue>15</issue><spage>1123</spage><epage>1131</epage><pages>1123-1131</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><coden>JNCIEQ</coden><abstract>Metformin is commonly prescribed to treat type 2 diabetes. Recent evidence suggests that it may possess antitumoral properties. The aim of this study was to test the association between metformin use and risk of prostate cancer and its grade among men with diabetes.
Data were obtained from population-based health-care administrative databases in Ontario, Canada. This retrospective cohort study used a nested case-control approach to examine the relationship between metformin exposure and the risk of prostate cancer within a cohort of incident diabetic men aged 66 years or older. We conducted four case-control analyses, defining case subjects as 1) any prostate cancer, 2) high-grade, 3) low-grade, and 4) biopsy-diagnosed. In each analysis, case subjects were matched to five control subjects on age and cohort entry date. Metformin exposure was determined based on prescriptions before cancer diagnosis, and adjusted odds ratios (aOR) were estimated using conditional logistic regression. All statistical tests were two-sided.
Within our cohort of 119 315 men with diabetes, there were 5306 case subjects with prostate cancer and 26 530 matched control subjects. Within the cancer case subjects, 1104 had high- grade cancer, 1719 had low-grade cancer, and 3524 had biopsy-diagnosed cancer. There was no association between metformin use and risk of any prostate cancer (aOR = 1.03, 95% confidence interval [CI] = 0.96 to 1.1), high-grade cancer (aOR = 1.13, 95% CI = 0.96 to 1.32), low-grade cancer (aOR = 0.94, 95% CI = 0.82 to 1.06), or biopsy-diagnosed cancer (aOR = 0.98, 95% CI = 0.84 to 1.02).
This large study did not find an association between metformin use and risk of prostate cancer among older men with diabetes, regardless of cancer grade or method of diagnosis.</abstract><cop>Cary, NC</cop><pub>Oxford University Press</pub><pmid>23853056</pmid><doi>10.1093/jnci/djt170</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 2013-08, Vol.105 (15), p.1123-1131 |
| issn | 0027-8874 1460-2105 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1437579022 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Age Aged Aged, 80 and over Biological and medical sciences Canada - epidemiology Case-Control Studies Databases, Factual Diabetes Diabetes Mellitus, Type 2 - drug therapy Drug Prescriptions Humans Hypoglycemic Agents - therapeutic use Logistic Models Male Medical research Medical sciences Mens health Metformin - therapeutic use Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Grading Nephrology. Urinary tract diseases Odds Ratio Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - pathology Prostatic Neoplasms - prevention & control Retrospective Studies Risk factors Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Association Between Metformin Use and Risk of Prostate Cancer and Its Grade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A05%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20Between%20Metformin%20Use%20and%20Risk%20of%20Prostate%20Cancer%20and%20Its%20Grade&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=MARGEL,%20David&rft.date=2013-08-07&rft.volume=105&rft.issue=15&rft.spage=1123&rft.epage=1131&rft.pages=1123-1131&rft.issn=0027-8874&rft.eissn=1460-2105&rft.coden=JNCIEQ&rft_id=info:doi/10.1093/jnci/djt170&rft_dat=%3Cproquest_cross%3E1437579022%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1420219184&rft_id=info:pmid/23853056&rfr_iscdi=true |